摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N(1-carbamoyl-1-oxo-3-phenyl-propan-2-yl)-2(E-2(4(1,2,5,6-tetrahydropyridin-1-yl-methyl)-phenyl)-ethen-1-yl)-benzamide | 247219-07-4

分子结构分类

中文名称
——
中文别名
——
英文名称
N(1-carbamoyl-1-oxo-3-phenyl-propan-2-yl)-2(E-2(4(1,2,5,6-tetrahydropyridin-1-yl-methyl)-phenyl)-ethen-1-yl)-benzamide
英文别名
N-(4-amino-3,4-dioxo-1-phenylbutan-2-yl)-2-[(E)-2-[4-(3,6-dihydro-2H-pyridin-1-ylmethyl)phenyl]ethenyl]benzamide
N(1-carbamoyl-1-oxo-3-phenyl-propan-2-yl)-2(E-2(4(1,2,5,6-tetrahydropyridin-1-yl-methyl)-phenyl)-ethen-1-yl)-benzamide化学式
CAS
247219-07-4
化学式
C31H31N3O3
mdl
——
分子量
493.605
InChiKey
NOGSNTZGSNIPDH-ISLYRVAYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.8
  • 重原子数:
    37
  • 可旋转键数:
    10
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.19
  • 拓扑面积:
    92.5
  • 氢给体数:
    2
  • 氢受体数:
    4

文献信息

  • Novel substituted amides, their preparation and use
    申请人:Abbott GmbH & Co., KG
    公开号:US20040082569A1
    公开(公告)日:2004-04-29
    An amide of the formula I 1 and its tautomeric forms, possible enantiomeric and diastereomeric forms, E and Z forms, and possible physiologically tolerated salts, in which the variables have the following meanings: A —(CH 2 ) p —R 1 , where R 1 can be pyrrolidine [sic], morpholine [sic], piperidine [sic], —NR 5 R 6 and 2 and R 5 , R 6 and R 7 can, independently of one another, be hydrogen, C 1 -C 4 -alkyl, CH 2 Ph, Ph, CH 2 CH 2 Ph, it also being possible for the phenyl rings to be substituted by R 6 , and p can be 1 and 2, and B can be phenyl [sic], pyridyl [sic], pyrimidyl [sic] and pyridazyl [sic], it also being possible for the rings to be substituted by up to 2 R 8 radicals, and D can be a bond, —(CH 2 ) m —, —CH═CH—, —C≡C—, and R 2 is chlorine, bromine, fluorine, C 1 -C 6 -alkyl, NHCO—C 1 -C 4 -alkyl, NHSO 2 —C 1 -C 4 -alkyl, NO 2 , —O—C 1 -C 4 -alkyl and NH 2 , and R 3 is —C 1 -C 6 -alkyl, branched or unbranched, and which may also carry a phenyl ring, indolyl ring or cyclohexyl ring which is in turn substituted by by [sic] a maximum of two R 8 radicals, where R 8 is hydrogen, C 1 -C 4 -alkyl, branched or unbranched, —O—C 1 -C 4 -alkyl, OH, Cl, F, Br, I, CF 3 , NO 2 , NH 2 , CN, COOH, COO—C 1 -C 4 -alkyl, NHCO—C 1 -C 4 -alkyl, —NHSO 2 -C 1 C 4 -alkyl and —SO 2 —C 1 -C 4 -alkyl; and Y is phenyl [sic], pyridine, pyrimidine and pyrazine and R 4 is hydrogen, COOR 9 and CO-Z in which Z is NR 10 R 11 and 3 R 9 is hydrogen, C 1 -C 6 -alkyl, linear or branched, and which may [lacuna] substituted by a phenyl ring which may itself also be substituted by one or two R 12 radicals, and R 10 is hydrogen, C 1 -C 6 -alkyl, linear or branched, and which may [lacuna] substituted by a phenyl ring which itself may also be substituted by one or two R 12 radicals, and 4 R 11 is hydrogen, C 1 -C 6 -alkyl, branched or unbranched, which may also be and [sic] substituted by a phenyl ring which may also carry an R 9 radical, and R 12 can be hydrogen, C 1 -C 4 -alkyl, branched or unbranched, —O—C 1 -C 4 -alkyl, OH, Cl, F, Br, I, CF 3 , NO 2 , NH 2 , CN, COOH, COO—C 1 -C 4 -alkyl, —NHCO—C 1 -C 4 -alkyl, —NHCO-phenyl, —NHSO 2 —C 1 -C 4 -alkyl, NHSO 2 -phenyl, —SO 2 —C 1 -C 4 -alkyl and —SO 2 -phenyl, R 13 is hydrogen, C 1 -C 6 -alkyl, linear or branched, and which may [lacuna] substituted by a phenyl ring which may itself also be substituted by one or two R 12 radicals, and R 14 is hydrogen, C 1 -C 6 -alkyl, linear or branched, and which may [lacuna] substituted by a phenyl ring which may itself also be substituted by one or two R 12 radicals, and n is a number 0, 1 or 2, and m,q are, independently of one another, a number 0, 1, 2, 3 or 4.
    公式I1的酰胺及其互变异构体、可能的对映异构体和顺反异构体、E和Z形式,以及可能的生理耐受盐,其中变量具有以下含义:A -(CH2)p-R1,其中R1可以是吡咯烷、吗啉、哌啶、-NR5R6和2,而R5、R6和R7可以独立地是氢、C1-C4-烷基、 Ph、Ph、 Ph,苯环也可以被R6取代,p可以是1和2,B可以是苯、吡啶嘧啶吡嗪,环也可以被最多2个R8基团取代,D可以是键、( )m、CH=CH、C≡C,R2是、C1-C6-烷基、NHCO-C1-C4-烷基、NHSO2-C1-C4-烷基、NO2、O-C1-C4-烷基和NH2,R3是C1-C6-烷基、支链或非支链,也可以携带苯环、吲哚环或环己烷环,该环可以被最多两个R8基团取代,其中R8是氢、C1-C4-烷基、支链或非支链、O-C1-C4-烷基、OH、Cl、F、Br、I、CF3、 、NH2、CN、COOH、COO-C1-C4-烷基、NHCO-C1-C4-烷基、NHSO2-C1C4-烷基和-SO2-C1-C4-烷基;Y是苯、吡啶嘧啶吡嗪,R4是氢、COOR9和CO-Z,其中Z是NR10R11和3,R9是氢、C1-C6-烷基、线性或支链,也可以被一个苯环取代,该苯环本身也可以被一个或两个R12基团取代,R10是氢、C1-C6-烷基、线性或支链,也可以被一个苯环取代,该苯环本身也可以被一个或两个R12基团取代,4R11是氢、C1-C6-烷基、支链或非支链,也可以被一个苯环取代,该苯环也可以携带一个R9基团,R12可以是氢、C1-C4-烷基、支链或非支链、O-C1-C4-烷基、OH、Cl、F、Br、I、 、 、NH2、CN、COOH、COO-C1-C4-烷基、NHCO-C1-C4-烷基、NHCO-苯基、NHSO2-C1-C4-烷基、NHSO2-苯基、SO2-C1-C4-烷基和SO2-苯基,R13是氢、C1-C6-烷基、线性或支链,也可以被一个苯环取代,该苯环本身也可以被一个或两个R12基团取代,R14是氢、C1-C6-烷基、线性或支链,也可以被一个苯环取代,该苯环本身也可以被一个或两个R12基团取代,n是0、1或2,m、q独立地是0、1、2、3或4的数字。
  • NOVEL SUBSTITUTED AMIDES, THEIR PREPARATION AND USE
    申请人:Treiber Hans-Jörg
    公开号:US20110275615A1
    公开(公告)日:2011-11-10
    An amide of the formula I and its tautomeric forms, possible enantiomeric and diastereomeric forms, E and Z forms, and possible physiologically tolerated salts, in which the variables have the following meanings: A —(CH 2 ) p —R 1 , where R 1 can be pyrrolidine, morpholine, piperidine, —NR 5 R 6 and and R 5 , R 6 and R 7 can, independently of one another, be hydrogen, C 1 -C 4 -alkyl, CH 2 Ph, Ph, CH 2 CH 2 Ph, it also being possible for the phenyl rings to be substituted by R 6 , and p can be 1 and 2, and B can be phenyl, pyridyl, pyrimidyl and pyridazyl, it also being possible for the rings to be substituted by up to 2 R 8 radicals, and D can be a bond, —(CH 2 ) m —, —CH═CH—, —C═C—, and R 2 is chlorine, bromine, fluorine, C 1 -C 6 -alkyl, NHCO—C 1 -C 4 -alkyl, NHSO 2 —C 1 -C 4 -alkyl, NO 2 , —O—C 1 -C 4 -alkyl and NH 2 , and R 3 is —C 1 -C 6 -alkyl, branched or unbranched, and which may also carry a phenyl ring, indolyl ring or cyclohexyl ring which is in turn substituted by a maximum of two R 8 radicals, where R 8 is hydrogen, C 1 -C 4 -alkyl, branched or unbranched, —O—C 1 -C 4 -alkyl, OH, Cl, F, Br, I, CF 3 , NO 2 , NH 2 , CN, COOH, COO—C 1 -C 4 -alkyl, NHCO—C 1 -C 4 -alkyl, —NHSO 2 —C 1 -C 4 -alkyl and —SO 2 —C 1 -C 4 -alkyl; and Y is phenyl, pyridine, pyrimidine and pyrazine and R 4 is hydrogen, COOR 9 and CO—Z in which Z is NR 10 R 11 and R 9 is hydrogen, C 1 -C 6 -alkyl, linear or branched, and which may [lacuna] substituted by a phenyl ring which may itself also be substituted by one or two R 12 radicals, and R 10 is hydrogen, C 1 -C 6 -alkyl, linear or branched, and which may [lacuna] substituted by a phenyl ring which itself may also be substituted by one or two R 12 radicals, and R 11 is hydrogen, C 1 -C 6 -alkyl, branched or unbranched, which may also be and substituted by a phenyl ring which may also carry an R9 radical, and R 12 can be hydrogen, C 1 -C 4 -alkyl, branched or unbranched, —O—C 1 -C 4 -alkyl, OH, Cl, F, Br, J, CF 3 , NO 2 , NH 2 , CN, COOH, COO—C 1 -C 4 -alkyl, —NHCO—C 1 -C 4 -alkyl, —NHCO-phenyl, —NHSO 2 —C 1 -C 4 -alkyl, NHSO 2 -phenyl, —SO 2 —C 1 -C 4 -alkyl and —SO 2 -phenyl, R 13 is hydrogen, C 1 -C 6 -alkyl, linear or branched, and which may [lacuna] substituted by a phenyl ring which may itself also be substituted by one or two R 12 radicals, and R 14 is hydrogen, C 1 -C 6 -alkyl, linear or branched, and which may [lacuna] substituted by a phenyl ring which may itself also be substituted by one or two R 12 radicals, and n is a number 0, 1 or 2, and m,q are, independently of one another, a number 0, 1, 2, 3 or 4.
    公式I的酰胺及其互变异构体、可能的对映异构体和顺反异构体、E和Z形式以及可能的生理耐受盐,其中变量具有以下含义: A - (CH2)p-R1,其中R1可以是吡咯烷、吗啉、哌啶、-NR5R6,R5、R6和R7可以独立地是氢、C1-C4烷基、 Ph、Ph、 Ph,苯环还可以被R6取代,p可以是1和2,而B可以是苯、吡啶嘧啶吡嗪,环也可以被多达2个R8基团取代,而D可以是键,- ( )m-,-CH═CH-,-C═C-,而R2是、C1-C6烷基、NHCO-C1-C4烷基、NHSO2-C1-C4烷基、NO2、-O-C1-C4烷基和NH2,而R3是C1-C6烷基,支链或直链,也可能带有苯环、吲哚环或环己基,该环也可能被多达两个R8基团取代,其中R8是氢、C1-C4烷基、支链或直链、-O-C1-C4烷基、OH、Cl、F、Br、I、CF3、 、NH2、CN、COOH、COO-C1-C4烷基、NHCO-C1-C4烷基、-NHSO2-C1-C4烷基和-SO2-C1-C4烷基;而Y是苯、吡啶嘧啶吡嗪,而R4是氢、COOR9和CO-Z,其中Z是NR10R11,而R9是氢、C1-C6烷基、线性或支链,也可能被苯环取代,该苯环本身也可能被一个或两个R12基团取代,而R10是氢、C1-C6烷基、线性或支链,也可能被苯环取代,该苯环本身也可能被一个或两个R12基团取代,而R11是氢、C1-C6烷基、支链或直链,也可能被一个苯环取代,该苯环也可能带有一个R9基团,而R12可以是氢、C1-C4烷基、支链或直链、-O-C1-C4烷基、OH、Cl、F、Br、J、 、 、NH2、CN、COOH、COO-C1-C4烷基、-NHCO-C1-C4烷基、-NHCO-苯基、-NHSO2-C1-C4烷基、NHSO2-苯基、-SO2-C1-C4烷基和-SO2-苯基,而R13是氢、C1-C6烷基、线性或支链,也可能被一个苯环取代,该苯环也可能带有一个或两个R12基团,而R14是氢、C1-C6烷基、线性或支链,也可能被一个苯环取代,该苯环也可能带有一个或两个R12基团,n是0、1或2,而m、q是独立的数字0、1、2、3或4。
  • NEUE SUBSTITUIERTE AMIDE, DEREN HERSTELLUNG UND ANWENDUNG
    申请人:Abbott GmbH & Co. KG
    公开号:EP1073641B1
    公开(公告)日:2004-04-14
  • US6753327B1
    申请人:——
    公开号:US6753327B1
    公开(公告)日:2004-06-22
  • US7276500B2
    申请人:——
    公开号:US7276500B2
    公开(公告)日:2007-10-02
查看更多

同类化合物

()-2-(5-甲基-2-氧代苯并呋喃-3(2)-亚乙基)乙酸乙酯 (甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (反式)-4-壬烯醛 (双(2,2,2-三氯乙基)) (乙腈)二氯镍(II) (乙基N-(1H-吲唑-3-基羰基)ethanehydrazonoate) (βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (±)17,18-二HETE (±)-辛酰肉碱氯化物 (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (s)-2,3-二羟基丙酸甲酯 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 ([2-(萘-2-基)-4-氧代-4H-色烯-8-基]乙酸) ([1-(甲氧基甲基)-1H-1,2,4-三唑-5-基](苯基)甲酮) (Z)-5-辛烯甲酯 (Z)-4-辛烯醛 (Z)-4-辛烯酸 (Z)-3-[[[2,4-二甲基-3-(乙氧羰基)吡咯-5-基]亚甲基]吲哚-2--2- (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-(-)-5'-苄氧基苯基卡维地洛 (S)-(-)-2-(α-(叔丁基)甲胺)-1H-苯并咪唑 (S)-(-)-2-(α-甲基甲胺)-1H-苯并咪唑 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-(+)-5,5'',6,6'',7,7'',8,8''-八氢-3,3''-二叔丁基-1,1''-二-2-萘酚,双钾盐 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-盐酸沙丁胺醇 (S)-溴烯醇内酯 (S)-氨氯地平-d4 (S)-氨基甲酸酯β-D-O-葡糖醛酸 (S)-8-氟苯并二氢吡喃-4-胺 (S)-7,7-双[(4S)-(苯基)恶唑-2-基)]-2,2,3,3-四氢-1,1-螺双茚满 (S)-4-(叔丁基)-2-(喹啉-2-基)-4,5-二氢噁唑 (S)-4-氯-1,2-环氧丁烷 (S)-3-(((2,2-二氟-1-羟基-7-(甲基磺酰基)-2,3-二氢-1H-茚满-4-基)氧基)-5-氟苄腈 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-3-(2-(二氟甲基)吡啶-4-基)-7-氟-3-(3-(嘧啶-5-基)苯基)-3H-异吲哚-1-胺 (S)-2-(环丁基氨基)-N-(3-(3,4-二氢异喹啉-2(1H)-基)-2-羟丙基)异烟酰胺 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[[[(1R,2R)-2-[[[3,5-双(叔丁基)-2-羟基苯基]亚甲基]氨基]环己基]硫脲基]-N-苄基-N,3,3-三甲基丁酰胺 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-2-N-Fmoc-氨基甲基吡咯烷盐酸盐 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (SP-4-1)-二氯双(喹啉)-钯 (SP-4-1)-二氯双(1-苯基-1H-咪唑-κN3)-钯